The global blood group typing market is poised to record significant growth through 2030. A sustainable rise in the number of road accidents and emergencies has elevated the need for blood transfusion and related blood group typing tests.

Ongoing blood shortages experienced by countries worldwide have supported new blood campaigns and donation drives. For instance, in September 2022, the Health Ministry of India announced a nationwide blood donation campaign to overcome the blood supply and demand disparity in the country.

Technological advancements in genetic engineering will advocate the introduction of RBC-based antigen genotyping that relies on next-generation sequencing (NGS) and high-density DNA arrays. In March 2022, Immucor launched MIA FOR A NGS EXPRESS, its latest HLA typing software to provide a value-added user experience to its customers. The new tool is designed to facilitate high-accuracy antigen typing capable of addressing the limitations of existing NGS products used in laboratories.

The blood group typing market is categorized into components, technique, test type, end-use, and region.

Based on component, the market is fragmented into consumables, services, and instruments. Among these, the service segment is projected to reach over USD 300 million through 2030. The availability of a range of blood group typing services enables accurate and faster analysis with the help of state-of-the-art software technologies. Software-integrated service enhances overall patient experience with improved clinical processes.

In terms of technique, the blood group typing industry is classified into next-generation sequencing (NGS), assay-based, PCR-based & microarray, and others. Next-generation sequencing (NGS) segment is expected to exhibit substantial growth from 2022-2030 owing to widespread usage in a variety of tests. NGS helps determine blood group antigens based on certain specific gene sequences.

By test type, the industry is bifurcated into ABO tests, antigen typing, cross-matching tests, antibody screening & identification, and others. Among these, antibody screening & identification, also known as antibody detection test, is applied to identify whether foreign antibodies or non-ABO antibodies are present/absent in the blood.

With respect to end-use, the blood group typing market is divided into blood banks, hospitals, laboratories, and others. In 2021, the hospitals segment held over 50% of the overall market share. High preference for hospitalized treatment among geriatric patients and individuals is expected to complement the segment growth.

Latin America blood group typing market valuation surpassed USD 150 million in 2021. Increasing focus on strengthening blood supply and growing number of blood donation drives and campaigns will foster business expansion. LATAM countries including Brazil, El Salvador, Peru, Uruguay, and Ecuador joined the Worldwide Blood Drive started by Intl. WeLoveU Foundation with the aim of addressing blood supply shortages intensified by the COVID-19 pandemic.